8 months in and orforglipron is still the thing I get wrong
8 months in and orforglipron is still the thing I get wrong, logged the same way every week so the comparison is at least internally fair.
The relevant figures are 8 months, and they come from the same log I have kept the whole time.
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
That is a phase 2 result being quoted as though the programme had reported.
I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.
Retitled to name the programme. It is what makes these threads findable in a year.
Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.
[deleted]
Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.
oral semaglutide is a peptide with an absorption enhancer, this is not that
the manufacturing story is genuinely different from the injectables
the manufacturing story is genuinely different from the injectables
Agreed, and it is why the oral peptide comparison keeps misleading people.
Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.
What did the tolerability table look like at that dose?
nothing containing this is approved anywhere yet
daily dosing changes adherence in both directions
Is that from the publication or the press release?
Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.
Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.
- 1the manufacturing story is genuinely different from the injectables7 comments in this branch · started by u/cato_batista